HRP20170295T1 - Oblik soli inhibitora ljudske histonske metiltransferaze ezh2 - Google Patents
Oblik soli inhibitora ljudske histonske metiltransferaze ezh2 Download PDFInfo
- Publication number
- HRP20170295T1 HRP20170295T1 HRP20170295TT HRP20170295T HRP20170295T1 HR P20170295 T1 HRP20170295 T1 HR P20170295T1 HR P20170295T T HRP20170295T T HR P20170295TT HR P20170295 T HRP20170295 T HR P20170295T HR P20170295 T1 HRP20170295 T1 HR P20170295T1
- Authority
- HR
- Croatia
- Prior art keywords
- degrees
- polymorph
- theta
- methyl
- diffraction pattern
- Prior art date
Links
- 101150090105 Ezh2 gene Proteins 0.000 title 1
- 102000011787 Histone Methyltransferases Human genes 0.000 title 1
- 108010036115 Histone Methyltransferases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003839 salts Chemical group 0.000 title 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 238000000034 method Methods 0.000 claims 5
- 239000002904 solvent Substances 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical compound C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 claims 3
- UQRICAQPWZSJNF-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide;hydrobromide Chemical compound Br.C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 UQRICAQPWZSJNF-UHFFFAOYSA-N 0.000 claims 3
- KLYFLPQLTNAFGR-UHFFFAOYSA-N 3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzoic acid Chemical compound C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(O)=O)=C(C)C=1N(CC)C1CCOCC1 KLYFLPQLTNAFGR-UHFFFAOYSA-N 0.000 claims 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical group COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000000113 differential scanning calorimetry Methods 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000002244 precipitate Substances 0.000 claims 2
- 238000001757 thermogravimetry curve Methods 0.000 claims 2
- VNBOAIXEUKYUJY-UHFFFAOYSA-N 3-(aminomethyl)-4,6-dimethyl-3,4-dihydro-1h-pyridin-2-one Chemical class CC1C=C(C)NC(=O)C1CN VNBOAIXEUKYUJY-UHFFFAOYSA-N 0.000 claims 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims 1
- 238000001953 recrystallisation Methods 0.000 claims 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims 1
- 235000005493 rutin Nutrition 0.000 claims 1
- 229960004555 rutoside Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
Claims (30)
1. N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-karboksamid hidrobromid.
2. Spoj prema zahtjevu 1, naznačen time da je monohidrobromid.
3. Spoj prema bilo kojem od zahtjeva 1-2, naznačen time da navedeni spoj je kristalan.
4. Spoj prema bilo kojem od gore navedenih zahtjeva, naznačen time da navedeni spoj je uglavnom bez nečistoća.
5. Spoj prema bilo kojem od gore navedenih zahtjeva, naznačen time da navedeni spoj je kristalna rutina uglavnom bez amorfnog N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-karboksamid hidrobromida.
6. Farmaceutski pripravak naznačen time da sadrži spoj prema bilo kojem od zahtjeva 1-5, te farmaceutski prihvatljiv nosač ili dodatak za otapanje.
7. Postupak za pripremanje spoja prema zahtjevu 1 naznačen time da sadrži miješanje N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-karboksamida s bromovodičnom kiselinom.
8. Polimorf A od N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil (tetrahidro-2H-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-karboksamid hidrobromida.
9. Polimorf prema zahtjevu 8, naznačen time da polimorf pokazuje uzorak difrakcije X-zraka na prahu koji ima one ili more karakterističnih vrškova izraženih u stupnjevima 2-theta kod oko 3.9 +/- 0.3 stupnjeva, oko 17.5 +/- 0.3 stupnjeva, te oko 22.0 +/- 0.3 stupnjeva 2-theta.
10. Polimorf prema bilo kojem od zahtjeva 8-9, naznačen time da polimorf pokazuje uzorak difrakcije X-zraka na prahu koji ima karakteristične vrškove izražene u stupnjevima 2-theta kod oko 3.9 +/- 0.3 stupnjeva, oko 17.5 +/- 0.3 stupnjeva, te oko 22.0 +/- 0.3 stupnjeva 2-theta.
11. Polimorf prema zahtjevu 8, naznačen time da polimorf pokazuje uzorak difrakcije X-zraka na prahu koji ima one ili more karakterističnih vrškova izraženih u stupnjevima 2-theta kod oko 3.9 +/- 0.3 stupnjeva, oko 14.3 +/- 0.3 stupnjeva, oko 18.7 +/- 0.3 stupnjeva, oko 23.3 +/- 0.3 stupnjeva, te oko 23.6 +/- 0.3 stupnjeva 2-theta.
12. Polimorf prema zahtjevu 8, naznačen time da polimorf pokazuje uzorak difrakcije X-zraka na prahu koji ima barem 5 karakterističnih vrškova izraženih u stupnjevima 2-theta kod oko 3.9 +/- 0.3 stupnjeva, 10.1 +/- 0.3 stupnjeva, 14.3 +/- 0.3 stupnjeva, 17.5 +/- 0.3 stupnjeva, 18.7 +/- 0.3 stupnjeva, 20.6 +/- 0.3 stupnjeva, 20.9 +/- 0.3 stupnjeva, 21.8 +/- 0.3 stupnjeva, 22.0 +/- 0.3 stupnjeva, 23.3 +/- 0.3 stupnjeva i 23.6 +/- 0.3 stupnjeva 2-theta.
13. Polimorf prema zahtjevu 8, naznačen time da polimorf pokazuje uzorak difrakcije X-zraka na prahu koji ima barem 6 karakterističnih vrškova izraženih u stupnjevima 2-theta kod oko 3.9 +/- 0.3 stupnjeva, 10.1 +/- 0.3 stupnjeva, 14.3 +/- 0.3 stupnjeva, 17.5 +/- 0.3 stupnjeva, 18.7 +/- 0.3 stupnjeva, 20.6 +/- 0.3 stupnjeva, 20.9 +/- 0.3 stupnjeva, 21.8 +/- 0.3 stupnjeva, 22.0 +/- 0.3 stupnjeva, 23.3 +/- 0.3 stupnjeva i 23.6 +/- 0.3 stupnjeva 2-theta.
14. Polimorf prema zahtjevu 8, naznačen time da polimorf pokazuje uzorak difrakcije X-zraka na prahu koji ima barem 7 karakterističnih vrškova izraženih u stupnjevima 2-theta kod oko 3.9 +/- 0.3 stupnjeva, 10.1 +/- 0.3 stupnjeva, 14.3 +/- 0.3 stupnjeva, 17.5 +/- 0.3 stupnjeva, 18.7 +/- 0.3 stupnjeva, 20.6 +/- 0.3 stupnjeva, 20.9 +/- 0.3 stupnjeva, 21.8 +/- 0.3 stupnjeva, 22.0 +/- 0.3 stupnjeva, 23.3 +/- 0.3 stupnjeva i 23.6 +/- 0.3 stupnjeva 2-theta.
15. Polimorf prema zahtjevu 8, naznačen time da polimorf pokazuje uzorak difrakcije X-zraka na prahu koji ima barem 8 karakterističnih vrškova izraženih u stupnjevima 2-theta kod oko 3.9 +/- 0.3 stupnjeva, 10.1 +/- 0.3 stupnjeva, 14.3 +/- 0.3 stupnjeva, 17.5 +/- 0.3 stupnjeva, 18.7 +/- 0.3 stupnjeva, 20.6 +/- 0.3 stupnjeva, 20.9 +/- 0.3 stupnjeva, 21.8 +/- 0.3 stupnjeva, 22.0 +/- 0.3 stupnjeva, 23.3 +/- 0.3 stupnjeva i 23.6 +/- 0.3 stupnjeva 2-theta.
16. Polimorf prema zahtjevu 8, naznačen time da polimorf pokazuje uzorak difrakcije X-zraka na prahu koji ima barem 9 karakterističnih vrškova izraženih u stupnjevima 2-theta kod oko 3.9 +/- 0.3 stupnjeva, 10.1 +/- 0.3 stupnjeva, 14.3 +/- 0.3 stupnjeva, 17.5 +/- 0.3 stupnjeva, 18.7 +/- 0.3 stupnjeva, 20.6 +/- 0.3 stupnjeva, 20.9 +/- 0.3 stupnjeva, 21.8 +/- 0.3 stupnjeva, 22.0 +/- 0.3 stupnjeva, 23.3 +/- 0.3 stupnjeva i 23.6 +/- 0.3 stupnjeva 2-theta.
17. Polimorf prema zahtjevu 8, naznačen time da polimorf pokazuje uzorak difrakcije X-zraka na prahu koji ima barem 10 karakterističnih vrškova izraženih u stupnjevima 2-theta kod oko 3.9 +/- 0.3 stupnjeva, 10.1 +/- 0.3 stupnjeva, 14.3 +/- 0.3 stupnjeva, 17.5 +/- 0.3 stupnjeva, 18.7 +/- 0.3 stupnjeva, 20.6 +/- 0.3 stupnjeva, 20.9 +/- 0.3 stupnjeva, 21.8 +/- 0.3 stupnjeva, 22.0 +/- 0.3 stupnjeva, 23.3 +/- 0.3 stupnjeva i 23.6 +/- 0.3 stupnjeva 2-theta.
18. Polimorf prema zahtjevu 8, naznačen time da polimorf pokazuje uzorak difrakcije X-zraka na prahu koji ima karakteristične vrškove izražene u stupnjevima 2-theta kod oko 3.9 +/- 0.3 stupnjeva, 10.1 +/- 0.3 stupnjeva, 14.3 +/- 0.3 stupnjeva, 17.5 +/- 0.3 stupnjeva, 18.7 +/- 0.3 stupnjeva, 20.6 +/- 0.3 stupnjeva, 20.9 +/- 0.3 stupnjeva, 21.8 +/- 0.3 stupnjeva, 22.0 +/- 0.3 stupnjeva, 23.3 +/- 0.3 stupnjeva i 23.6 +/- 0.3 stupnjeva 2-theta.
19. Polimorf prema bilo kojem od zahtjeva 8-18, naznačen time da polimorf pokazuje uzorak difrakcije X-zraka na prahu uglavnom u skladu sa Slikom 1.
20. Polimorf prema bilo kojem od zahtjeva 8-19, naznačen time da polimorf pokazuje uzorak difrakcije X-zraka na prahu uglavnom u skladu s tablicom 1.
21. Polimorf prema bilo kojem od zahtjeva 8-20, naznačen time da polimorf pokazuje termogram diferencijalne pretražne kalorimetrije koji ima karakteristični vršak izražen u jedinicama °C kod temperature od 255 +/- 5°C.
22. Polimorf prema bilo kojem od zahtjeva 8-21, naznačen time da polimorf pokazuje termogram diferencijalne pretražne kalorimetrije uglavnom u skladu sa Slikom 3.
23. Postupak za pripremanje polimorfa prema bilo kojem od zahtjeva 8-22, naznačen time da sadrži miješanje N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-karboksamida s bromovodičnom kiselinom.
24. Postupak rekristalizacije polimorfa prema bilo kojem od zahtjeva 8-22, naznačen time da sadrži slijedeće korake: (a) otapanje Polimorfa A u prvom otapalu, te (b) dodavanje drugog otapala, tako da se navedeni polimorf rekristalizira.
25. Postupak prema zahtjevu 24, naznačen time da prvo otapalo je etanol, a drugo otapalo je MTBE.
26. Postupak prema zahtjevu 16, naznačen time da sadrži (a) otapanje Polimorfa A u etanolu, (b) zagrijavanje smjese, (c) dodavanje MTBE u smjesu, stvaranje taloga koji sadrži navedeni polimorf, te filtriranje taloga tako da se navedeni polimorf rekristalizira.
27. Farmaceutski pripravak naznačen time da sadrži polimorf prema bilo kojem od zahtjeva 8-22, i farmaceutski prihvatljiv nosač ili dodatak za otapanje.
28. Spoj prema bilo kojem od zahtjeva 1-5, polimorf prema bilo kojem od zahtjeva 8-22, ili farmaceutski pripravak prema bilo kojem od zahtjeva 6 ili 27 naznačen time da je za uporabu u postupku liječenja raka.
29. Spoj, polimorf, ili farmaceutski pripravak za uporabu prema zahtjevu 28, naznačen time da rak je ne-Hodgkinov limfom, folikularni limfom (FL), difuzni limfom velikih B-stanica (DLBCL), ili rak dojke.
30. Postupak za pripremanje N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil (tetrahidro-2H-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-karboksamida naznačen time da sadrži reakciju 5-(etil(tetrahidro-2H-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-karboksilne kiseline (5) sa soli 3-(aminometil)-4,6-dimetil-dihidro-piridin-2(1H)-ona.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624215P | 2012-04-13 | 2012-04-13 | |
| PCT/US2013/036193 WO2013155317A1 (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
| EP13774979.2A EP2836491B1 (en) | 2012-04-13 | 2013-04-11 | Salt form of a human histone methyltransferase ezh2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170295T1 true HRP20170295T1 (hr) | 2017-04-21 |
Family
ID=49328166
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170295TT HRP20170295T1 (hr) | 2012-04-13 | 2017-02-22 | Oblik soli inhibitora ljudske histonske metiltransferaze ezh2 |
| HRP20191653TT HRP20191653T1 (hr) | 2012-04-13 | 2019-09-13 | N-((4,6-dimetil-2-okso-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2h-piran-4-il)amino)-4-metil-4' (morfolinometil)-[l,1'-bifenil]-3-karboksamid hidrobromid za uporabu u liječenju proliferativnih poremećaja stanica hematološkog sustava |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191653TT HRP20191653T1 (hr) | 2012-04-13 | 2019-09-13 | N-((4,6-dimetil-2-okso-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2h-piran-4-il)amino)-4-metil-4' (morfolinometil)-[l,1'-bifenil]-3-karboksamid hidrobromid za uporabu u liječenju proliferativnih poremećaja stanica hematološkog sustava |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US9394283B2 (hr) |
| EP (4) | EP3628670B1 (hr) |
| JP (3) | JP6255382B2 (hr) |
| KR (3) | KR102120883B1 (hr) |
| CN (2) | CN104603130B (hr) |
| AU (2) | AU2013245878B2 (hr) |
| BR (1) | BR112014025508B1 (hr) |
| CA (1) | CA2870005C (hr) |
| CY (2) | CY1119383T1 (hr) |
| DK (3) | DK3628670T3 (hr) |
| ES (3) | ES2931316T3 (hr) |
| HR (2) | HRP20170295T1 (hr) |
| HU (3) | HUE060881T2 (hr) |
| IL (4) | IL282732B2 (hr) |
| IN (1) | IN2014DN09068A (hr) |
| LT (2) | LT3184523T (hr) |
| MX (1) | MX362339B (hr) |
| NZ (1) | NZ700761A (hr) |
| PL (3) | PL3184523T3 (hr) |
| PT (3) | PT3184523T (hr) |
| RS (2) | RS59392B1 (hr) |
| RU (1) | RU2658911C2 (hr) |
| SG (3) | SG10201608577RA (hr) |
| SI (2) | SI3184523T1 (hr) |
| WO (1) | WO2013155317A1 (hr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| WO2013075084A1 (en) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9085583B2 (en) | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| RU2658911C2 (ru) | 2012-04-13 | 2018-06-26 | Эпизайм, Инк. | Солевая форма ингибитора гистон-метилтрансферазы ezh2 человека |
| WO2013155464A1 (en) | 2012-04-13 | 2013-10-17 | Epizyme, Inc. | Combination therapy for treating cancer |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| US10092572B2 (en) * | 2012-10-15 | 2018-10-09 | Epizyme, Inc. | Substituted benzene compounds |
| NZ746054A (en) | 2012-10-15 | 2020-07-31 | Epizyme Inc | Methods of treating cancer |
| WO2014151142A1 (en) | 2013-03-15 | 2014-09-25 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| SG11201508203TA (en) | 2013-04-30 | 2015-11-27 | Glaxosmithkline Ip No 2 Ltd | Enhancer of zeste homolog 2 inhibitors |
| US9556157B2 (en) | 2013-07-10 | 2017-01-31 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| EA038869B1 (ru) | 2013-10-16 | 2021-10-29 | Эпизим, Инк. | Кристаллические формы гидрохлорида n-((4,6-диметил-2-оксо-1,2-дигидропиридин-3-ил)метил)-5-(этил(тетрагидро-2h-пиран-4-ил)амино)-4-метил-4'-(морфолинометил)-[1,1'-бифенил]-3-карбоксамида, фармацевтические композиции на их основе и способы их применения |
| JP2016533364A (ja) * | 2013-10-18 | 2016-10-27 | エピザイム，インコーポレイティド | 癌を処置する方法 |
| US9738630B2 (en) | 2013-11-19 | 2017-08-22 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
| CN116019921A (zh) | 2013-12-06 | 2023-04-28 | Epizyme股份有限公司 | 用于治疗癌症的组合疗法 |
| SG10201811128RA (en) | 2014-06-17 | 2019-01-30 | Epizyme Inc | Ezh2 inhibitors for treating lymphoma |
| ES2725928T3 (es) | 2014-06-20 | 2019-09-30 | Constellation Pharmaceuticals Inc | Formas cristalinas de 2-((4S)-6-(4-clorofenil)-1-metil-4H-benzo[c]isoxazolo[4,5-e]azepin-4-il)acetamida |
| JP2017532338A (ja) | 2014-10-16 | 2017-11-02 | エピザイム，インコーポレイティド | 癌を治療する方法 |
| ES2947819T3 (es) * | 2014-11-17 | 2023-08-21 | Epizyme Inc | Método para el tratamiento del cáncer con N-((4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-carboxamida |
| TW201636344A (zh) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| JP2018513865A (ja) | 2015-04-20 | 2018-05-31 | エピザイム，インコーポレイティド | 癌を処置するための併用療法 |
| JP6890097B2 (ja) | 2015-06-10 | 2021-06-18 | エピザイム，インコーポレイティド | リンパ腫を処置するためのｅｚｈ２阻害剤 |
| KR20180042356A (ko) | 2015-08-24 | 2018-04-25 | 에피자임, 인코포레이티드 | 암 치료 방법 |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| JP2019503391A (ja) | 2016-01-29 | 2019-02-07 | エピザイム，インコーポレイティド | 癌を処置するための併用療法 |
| JP7121660B2 (ja) | 2016-06-01 | 2022-08-18 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤の使用 |
| EP3471830A4 (en) | 2016-06-17 | 2020-02-26 | Epizyme Inc | EZH2 INHIBITORS TO TREAT CANCER |
| CN109843870A (zh) | 2016-10-19 | 2019-06-04 | 星座制药公司 | Ezh2抑制剂的合成 |
| US11214561B2 (en) * | 2017-01-25 | 2022-01-04 | Ancureall Pharmaceutical (Shanghai) Co., Ltd. | Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof |
| WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| WO2018223030A1 (en) | 2017-06-02 | 2018-12-06 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| CA3074720A1 (en) | 2017-09-05 | 2019-03-14 | Epizyme, Inc. | Combination therapy for treating cancer |
| CA3104209A1 (en) | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| KR20220066892A (ko) | 2019-08-22 | 2022-05-24 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｔ 세포 요법 및 제스트 동족체 2의 인핸서 (ｅｚｈ2) 억제제의 병용 요법 및 관련 방법 |
| BR112022012258A2 (pt) * | 2019-12-20 | 2022-08-30 | Epizyme Inc | Sal cristalino de bromidreto de um inibidor de ezh2, sua preparação e composição farmacêutica útil para o tratamento de câncer |
| WO2022208552A1 (en) * | 2021-03-31 | 2022-10-06 | Msn Laboratories Private Limited, R&D Center | Crystalline forms of [1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) and process for its preparation thereof |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0733729A (ja) | 1993-07-26 | 1995-02-03 | Kirin Brewery Co Ltd | Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法 |
| ATE180468T1 (de) | 1993-12-27 | 1999-06-15 | Eisai Co Ltd | Anthranilsäure derivate |
| DE19516776A1 (de) | 1995-05-10 | 1996-11-14 | Boehringer Ingelheim Int | Chromatin-Regulatorgene |
| US5741819A (en) | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
| JP3906935B2 (ja) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| AU6060099A (en) | 1998-09-30 | 2000-04-17 | Procter & Gamble Company, The | 2-substituted ketoamides |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| TWI287004B (en) | 2000-12-28 | 2007-09-21 | Shionogi & Co | A pyridone derivative having an affinity effect for cannabinoid 2 type receptor |
| US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
| TW200303304A (en) * | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| ES2333214T3 (es) | 2002-02-19 | 2010-02-18 | SHIONOGI & CO., LTD. | Antipruriticos. |
| TW200306155A (en) | 2002-03-19 | 2003-11-16 | Du Pont | Benzamides and advantageous compositions thereof for use as fungicides |
| US7442685B2 (en) | 2003-06-13 | 2008-10-28 | The University Of North Carolina At Chapel Hill | DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia |
| JP2007531757A (ja) * | 2004-03-30 | 2007-11-08 | カイロン コーポレイション | 抗癌剤としての置換チオフェン誘導体 |
| JP5160885B2 (ja) | 2004-06-01 | 2013-03-13 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 再構成ヒストンメチルトランスフェラーゼ複合体及びそのモジュレーターの識別方法 |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| WO2006130720A2 (en) | 2005-06-02 | 2006-12-07 | University Of North Carolina At Chapel Hill | Purification, characterization and reconstitution of a ubiquitin e3 ligase |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| NZ593684A (en) | 2005-10-19 | 2012-11-30 | Gruenenthal Chemie | Novel vanilloid receptor ligands and their use for producing medicaments |
| CN101291910A (zh) | 2005-10-21 | 2008-10-22 | 默克公司 | 钾通道抑制剂 |
| WO2007053480A2 (en) | 2005-10-28 | 2007-05-10 | The University Of North Carolina At Chapel Hill | Protein demethylases comprising a jmjc domain |
| US8163749B2 (en) | 2005-12-14 | 2012-04-24 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US8524467B2 (en) | 2006-01-20 | 2013-09-03 | The University Of North Carolina At Chapel Hill | Diagnostic and therapeutic targets for leukemia |
| KR20080110905A (ko) | 2006-05-15 | 2008-12-19 | 아이알엠 엘엘씨 | 테레프탈라메이트 화합물 및 조성물, 및 ｈｉｖ 인테그라제억제제로서의 그들의 용도 |
| WO2007136592A2 (en) | 2006-05-18 | 2007-11-29 | Amphora Discovery Corporation | 2-0x0-l,2-dihydr0quin0line derivatives, compositions, and uses thereof as antiproliferative agents |
| WO2008108825A2 (en) | 2006-10-10 | 2008-09-12 | Burnham Institute For Medical Research | Neuroprotective compositions and methods |
| MX2009008531A (es) | 2007-02-16 | 2009-08-26 | Amgen Inc | Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met. |
| WO2008104077A1 (en) | 2007-02-28 | 2008-09-04 | Methylgene Inc. | Small molecule inhibitors of protein arginine methyltransferases (prmts) |
| WO2008113006A1 (en) | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
| DE102007017884A1 (de) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| US20090012031A1 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | EZH2 Cancer Markers |
| DE102007047737A1 (de) * | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
| AU2008319308B2 (en) | 2007-10-31 | 2013-01-31 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
| WO2009077766A1 (en) | 2007-12-19 | 2009-06-25 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| WO2009124137A2 (en) | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Method of suppressing gene transcription through histone lysine methylation |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| AU2009279616A1 (en) | 2008-08-08 | 2010-02-11 | New York Blood Center | Small molecule inhibitors of retroviral assembly and maturation |
| FR2934995B1 (fr) | 2008-08-14 | 2010-08-27 | Sanofi Aventis | Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique |
| WO2010111653A2 (en) | 2009-03-27 | 2010-09-30 | The Uab Research Foundation | Modulating ires-mediated translation |
| WO2011011366A2 (en) | 2009-07-20 | 2011-01-27 | Constellation Pharmaceuticals | Agents for stimulating activity of methyl modifying enzymes and methods of use thereof |
| CA2784899A1 (en) | 2009-12-30 | 2011-07-07 | Avon Products, Inc. | Topical lightening composition and uses thereof |
| ES2528269T3 (es) * | 2010-05-07 | 2015-02-06 | Glaxosmithkline Llc | Azaindazoles |
| WO2011140325A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
| SI2566327T1 (sl) * | 2010-05-07 | 2017-07-31 | Glaxosmithkline Llc | Indoli |
| KR102373074B1 (ko) | 2010-09-10 | 2022-03-11 | 에피자임, 인코포레이티드 | 인간 ｅｚｈ2의 억제제 및 이의 사용 방법 |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP5908493B2 (ja) | 2010-12-01 | 2016-04-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | インドール |
| AU2011336272A1 (en) | 2010-12-03 | 2013-06-20 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TWI598336B (zh) | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| KR102587175B1 (ko) | 2012-03-12 | 2023-10-06 | 에피자임, 인코포레이티드 | 인간 ｅｚｈ2의 억제제 및 이의 사용 방법 |
| RU2658911C2 (ru) | 2012-04-13 | 2018-06-26 | Эпизайм, Инк. | Солевая форма ингибитора гистон-метилтрансферазы ezh2 человека |
| WO2013155464A1 (en) | 2012-04-13 | 2013-10-17 | Epizyme, Inc. | Combination therapy for treating cancer |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| NZ746054A (en) | 2012-10-15 | 2020-07-31 | Epizyme Inc | Methods of treating cancer |
| EA038869B1 (ru) | 2013-10-16 | 2021-10-29 | Эпизим, Инк. | Кристаллические формы гидрохлорида n-((4,6-диметил-2-оксо-1,2-дигидропиридин-3-ил)метил)-5-(этил(тетрагидро-2h-пиран-4-ил)амино)-4-метил-4'-(морфолинометил)-[1,1'-бифенил]-3-карбоксамида, фармацевтические композиции на их основе и способы их применения |
-
2013
- 2013-04-11 RU RU2014145544A patent/RU2658911C2/ru not_active Application Discontinuation
- 2013-04-11 HU HUE19180479A patent/HUE060881T2/hu unknown
- 2013-04-11 EP EP19180479.8A patent/EP3628670B1/en active Active
- 2013-04-11 SG SG10201608577RA patent/SG10201608577RA/en unknown
- 2013-04-11 KR KR1020147030684A patent/KR102120883B1/ko active IP Right Grant
- 2013-04-11 CN CN201380030902.3A patent/CN104603130B/zh active Active
- 2013-04-11 PL PL16191716T patent/PL3184523T3/pl unknown
- 2013-04-11 HU HUE13774979A patent/HUE031976T2/en unknown
- 2013-04-11 IL IL282732A patent/IL282732B2/en unknown
- 2013-04-11 EP EP13774979.2A patent/EP2836491B1/en active Active
- 2013-04-11 MX MX2014012380A patent/MX362339B/es active IP Right Grant
- 2013-04-11 KR KR1020227029511A patent/KR20220123339A/ko not_active Application Discontinuation
- 2013-04-11 LT LTEP16191716.6T patent/LT3184523T/lt unknown
- 2013-04-11 CN CN201810245662.3A patent/CN108358899B/zh active Active
- 2013-04-11 RS RSP20191175 patent/RS59392B1/sr unknown
- 2013-04-11 JP JP2015505912A patent/JP6255382B2/ja active Active
- 2013-04-11 IL IL296199A patent/IL296199A/en unknown
- 2013-04-11 SG SG10201912109QA patent/SG10201912109QA/en unknown
- 2013-04-11 DK DK19180479.8T patent/DK3628670T3/da active
- 2013-04-11 WO PCT/US2013/036193 patent/WO2013155317A1/en active Application Filing
- 2013-04-11 ES ES19180479T patent/ES2931316T3/es active Active
- 2013-04-11 NZ NZ700761A patent/NZ700761A/en unknown
- 2013-04-11 LT LTEP13774979.2T patent/LT2836491T/lt unknown
- 2013-04-11 EP EP22200677.7A patent/EP4190777A1/en active Pending
- 2013-04-11 DK DK16191716.6T patent/DK3184523T3/da active
- 2013-04-11 RS RS20170198A patent/RS55690B1/sr unknown
- 2013-04-11 CA CA2870005A patent/CA2870005C/en active Active
- 2013-04-11 ES ES13774979.2T patent/ES2617379T3/es active Active
- 2013-04-11 DK DK13774979.2T patent/DK2836491T3/en active
- 2013-04-11 SG SG11201406468YA patent/SG11201406468YA/en unknown
- 2013-04-11 IN IN9068DEN2014 patent/IN2014DN09068A/en unknown
- 2013-04-11 ES ES16191716T patent/ES2745016T3/es active Active
- 2013-04-11 PL PL13774979T patent/PL2836491T3/pl unknown
- 2013-04-11 HU HUE16191716A patent/HUE045353T2/hu unknown
- 2013-04-11 PT PT16191716T patent/PT3184523T/pt unknown
- 2013-04-11 KR KR1020207015664A patent/KR102438340B1/ko active IP Right Grant
- 2013-04-11 SI SI201331566T patent/SI3184523T1/sl unknown
- 2013-04-11 US US14/394,431 patent/US9394283B2/en active Active
- 2013-04-11 EP EP16191716.6A patent/EP3184523B1/en active Active
- 2013-04-11 PL PL19180479.8T patent/PL3628670T3/pl unknown
- 2013-04-11 PT PT137749792T patent/PT2836491T/pt unknown
- 2013-04-11 SI SI201330551A patent/SI2836491T1/sl unknown
- 2013-04-11 BR BR112014025508-3A patent/BR112014025508B1/pt active IP Right Grant
- 2013-04-11 AU AU2013245878A patent/AU2013245878B2/en active Active
- 2013-04-11 PT PT191804798T patent/PT3628670T/pt unknown
-
2014
- 2014-10-07 IL IL235045A patent/IL235045B/en active IP Right Grant
-
2016
- 2016-06-30 US US15/199,522 patent/US9872862B2/en active Active
-
2017
- 2017-02-22 HR HRP20170295TT patent/HRP20170295T1/hr unknown
- 2017-03-06 CY CY20171100290T patent/CY1119383T1/el unknown
- 2017-10-12 JP JP2017198642A patent/JP6634058B2/ja active Active
- 2017-12-11 US US15/837,390 patent/US10245269B2/en active Active
-
2018
- 2018-01-09 AU AU2018200168A patent/AU2018200168B2/en active Active
- 2018-10-02 JP JP2018187463A patent/JP2018199740A/ja active Pending
-
2019
- 2019-02-08 US US16/270,752 patent/US10821113B2/en active Active
- 2019-04-21 IL IL266165A patent/IL266165B/en active IP Right Grant
- 2019-09-13 HR HRP20191653TT patent/HRP20191653T1/hr unknown
- 2019-09-18 CY CY20191100981T patent/CY1122883T1/el unknown
-
2020
- 2020-09-25 US US17/032,432 patent/US11491163B2/en active Active
-
2022
- 2022-09-29 US US17/936,555 patent/US20230140327A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170295T1 (hr) | Oblik soli inhibitora ljudske histonske metiltransferaze ezh2 | |
| JP2015512942A5 (hr) | ||
| JP6736559B2 (ja) | トリアゾロピリミジン化合物およびその使用 | |
| AU2016282289B2 (en) | HPK1 inhibitors and methods of using same | |
| JP7279057B2 (ja) | Ｐｄ１／ｐｄ－ｌ１活性化の阻害剤としてのピリミジン誘導体 | |
| KR102588955B1 (ko) | 이환식 화합물 및 암의 치료에서의 이의 용도 | |
| JP2024059874A (ja) | ＳＨＰ２のオクタヒドロシクロペンタ［ｃ］ピロールのアロステリック阻害剤 | |
| US11065226B2 (en) | Combination comprising EP4 antagonist and immune checkpoint inhibitor | |
| FI3057962T3 (fi) | Hydrokloridisuolamuoto ezh2-estoon | |
| JP2019524872A (ja) | 癌の治療に有用なイミダゾピリミジン化合物 | |
| AU2017279027A1 (en) | Chemical Compounds | |
| EP3820843A1 (en) | Chemical compounds | |
| HRP20240304T1 (hr) | Soli valbenazin dihidroklorida i njihovi polimorfi | |
| WO2019193540A1 (en) | Heteroaryl derivatives of formula (i) as atf4 inhibitors | |
| EP3649106A1 (en) | N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1-carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases | |
| EP3649108A1 (en) | 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases | |
| KR20180004811A (ko) | 인돌아민 2,3-디옥시게나제의 억제제로서의 활성을 갖는 벤즈이미다졸 및 이미다조피리딘 카르복스이미드아미드 화합물 | |
| JP2009534358A5 (hr) | ||
| HRP20110156T1 (hr) | Monociklički heterocikli kao inhibitori kinaze | |
| AU2014205316A1 (en) | (Hetero) arylacetamide derivatives as antiretroviral agents | |
| CA3149304A1 (en) | Deuterated mk2 pathway inhibitors and methods of using the same | |
| TW201630891A (zh) | 三環性螺化合物 | |
| JP6681517B2 (ja) | ｍＧｌｕＲ２陰性アロステリック調節剤としてのクロマン、イソクロマン及びジヒドロイソベンゾフラン誘導体、組成物、及びそれらの使用 | |
| HRP20192279T1 (hr) | Novi spojevi imidazopiridazina i njihova uporaba | |
| KR20200040764A (ko) | 1,8-나프티리디논 화합물 및 그의 용도 |